A Phase 3 interventional study of Astegolimab and Placebo in Chronic Obstructive Pulmonary Disease (COPD), sponsored by Hoffmann-La Roche. Completed at 348 sites in 36 countries. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-28.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Pulmonary Disease, Chronic Obstructive by Hoffmann-La Roche — 1 open to participants now, 2 under way, 1 of them phase 3. Pulmonary Disease, Chronic Obstructive · Hoffmann-La Roche.
Among the 10 studies in Pulmonary Disease, Chronic Obstructive by Hoffmann-La Roche, this one is the only one that started in 2022, is one of 2 in phase 3, and was the 5th registered.
5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →1 of the 10 studies in Pulmonary Disease, Chronic Obstructive by Hoffmann-La Roche is open now, in 1 country. Recruiting first, the newest first:
Hoffmann-La Roche · Sites in United Kingdom
Ages 18–80 · Healthy volunteers
By country, each count listing its studies:
Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.
This study: 40 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 5 · Phase 3 2
First in 2009; this study’s year is marked. 1 started in 2022.
This study's enrollment of 1,380 is above the median of 62 across 3,841 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 104 across the 9 interventional studies, 0 across the 1 observational. Of the 6 that completed or were terminated, 5 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
1 of the studies in Pulmonary Disease, Chronic Obstructive by Hoffmann-La Roche that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05878769Phase 3Hoffmann-La RocheA Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD) | 2027-06-30 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies in Pulmonary Disease, Chronic Obstructive by Hoffmann-La Roche, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the efficacy and safety of astegolimab compared with placebo in participants with chronic obstructive pulmonary disease (COPD) who are former or current smokers and have a history of frequent exacerbations.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive subcutaneous (SC) astegolimab every 2 weeks (Q2W)
Drug: Astegolimab
Participants will receive alternating SC astegolimab and placebo Q2W, thus receiving SC astegolimab Q4W.
Drug: Astegolimab
Participants will receive SC placebo Q2W
Drug: Placebo
Participants will receive SC astegolimab Q2W or Q4W
Participants will receive SC placebo Q2W
Annualized Rate of Moderate and Severe COPD Exacerbations Over the 52-week Treatment Period
A moderate COPD exacerbation was defined as new or increased COPD symptoms (e.g., dyspnea, sputum volume, and sputum purulence) that lead to treatment (duration ≥ 3 days) with systemic corticosteroids (oral, intravenous \[IV\], or intramuscular \[IM\]) at a dose of \> 10 milligrams per day (mg/day) prednisolone equivalent and/or antibiotics. A severe COPD exacerbation was defined as new or increased COPD symptoms that lead to hospitalization (duration \> 24 hours) or death. The unadjusted AER was estimated as the total number of exacerbations observed over the treatment period divided by the total participant-years at risk (participant-years = date of first study drug administration to completion or discontinuation during the double-blind treatment period divided by 365.25 days). The adjusted AER was estimated using negative binomial regression. Adjusted rate values have been reported. A method of dispersion was not specified in the SAP.
Time frame: Up to 52 weeks
Annualized Rate of Moderate and Severe COPD Exacerbations Over the 52-week Treatment Period in Participants With Low Baseline Blood Eosinophil Level (<300 Cells Per Microliter [Cells/µL])
A moderate COPD exacerbation was defined as new or increased COPD symptoms (e.g., dyspnea, sputum volume, and sputum purulence) that lead to treatment (duration ≥ 3 days) with systemic corticosteroids (oral, intravenous \[IV\], or intramuscular \[IM\]) at a dose of \> 10 milligrams per day (mg/day) prednisolone equivalent and/or antibiotics. A severe COPD exacerbation was defined as new or increased COPD symptoms that lead to hospitalization (duration \> 24 hours) or death. The unadjusted AER was estimated as the total number of exacerbations observed over the treatment period divided by the total participant-years at risk (participant-years = date of first study drug administration to completion or discontinuation during the double-blind treatment period divided by 365.25 days). The adjusted AER was estimated using negative binomial regression. Adjusted rate values have been reported A method of dispersion was not specified in the SAP.
Time frame: Up to 52 weeks
Time to First Moderate or Severe COPD Exacerbation During the 52-week Treatment Period
Time to first moderate or severe COPD exacerbation was defined as the time from the first administration of study drug to the first incidence of moderate or severe COPD exacerbation event during the 52-week treatment period. A moderate COPD exacerbation was defined as new or increased COPD symptoms (e.g., dyspnea, sputum volume, and sputum purulence) that lead to treatment (duration ≥3 days) with systemic corticosteroids (oral, IV, or IM) at a dose of \>10 mg/day prednisolone equivalent and/or antibiotics. A severe COPD exacerbation was defined as new or increased COPD symptoms that lead to hospitalization (duration \> 24 hours) or death. Kaplan-Meier (K-M) method was used to estimate the median time.
Time frame: Up to 52 weeks
Absolute Change From Baseline in Health-related Quality-of-life (HRQoL) at Week 52, as Assessed Through the Saint George's Respiratory Questionnaire-COPD (SGRQ-C) Total Score
SGRQ-C is a disease-specific, self-administered instrument designed to assess the impact of COPD on participants' health status and well-being based on their perception of COPD-related experiences. The questionnaire consists of 40 items across three sub-domains: symptoms (respiratory symptoms and severity- 7 items), activity (activities causing or limited by breathlessness-13 items) and impacts (social functioning and psychological disturbances due to airway disease- 20 items). Each response is assigned a unique empirically derived weight. Total score is calculated by summing the weights to all the positive responses across each domain, with scores ranging from 0 (no impairment) to 100 (maximum impairment), with lower scores indicating better HRQoL. Adjusted mean of change from baseline (CFB) is reported here.
Time frame: At Week 52
Absolute Change From Baseline in Post-bronchodilator Forced Expiratory Volume in 1 Second (FEV1) (Liters) at Week 52
Post-bronchodilator FEV1 was defined as the FEV1 value measured with spirometry 20-30 minutes after bronchodilator use. Maximal bronchodilation was achieved via administration of either albuterol (90 micrograms \[µg\] metered dose) or salbutamol (100 µg metered dose), with or without a spacer device, up to a maximum of 4 inhalations. Adjusted mean of CFB is reported here.
Time frame: At Week 52
Absolute Change From Baseline in Evaluating Respiratory Symptoms in COPD (E-RS: COPD) Total Score at Week 52
The EXAcerbations of Chronic Pulmonary Disease Tool (EXACT) is a 14-item participant-reported instrument used to assess the frequency, severity, and duration of COPD exacerbations using a daily electronic diary (eDiary). It includes four domains: breathlessness (5 items), cough and sputum (3 items), chest symptoms (3 items), and additional attributes (tired or weak, sleep disturbance, and scared or worried; 3 items). The E-RS:COPD is an 11-item subset of the EXACT designed to assess the severity of cardinal respiratory symptoms of COPD, including breathlessness, cough, sputum, chest congestion, and chest tightness. It consists of three subscales: RS-Breathlessness, RS-Cough \& Sputum, and RS-Chest Symptoms. Items are scored on 5- or 6-point Likert scales, and the total score is calculated by summing the item scores, ranging from 0 (no impact) to 40 (high impact), with higher scores indicating greater symptom severity. Adjusted mean of CFB is reported here.
Time frame: At Week 52
Percentage of Participants With Improvement in HRQoL at Week 52, as Assessed by SGRQ-C
Percentage of participants with SGRQ-C improvement was defined as the percentage of participants with an absolute decrease from baseline of ≥4 points in SGRQ-C total score. SGRQ-C is a disease-specific, self-administered instrument designed to assess the impact of COPD on participants' health status and well-being based on their perception of COPD-related experiences. The questionnaire consists of 40 items across three sub-domains: symptoms (respiratory symptoms and severity- 7 items), activity (activities causing or limited by breathlessness-13 items) and impacts (social functioning and psychological disturbances due to airway disease- 20 items). Each response is assigned a unique empirically derived weight. Total score is calculated by summing the weights to all the positive responses across each domain, with scores ranging from 0 (no impairment) to 100 (maximum impairment), with lower scores indicating better HRQoL.
Time frame: At Week 52
Annualized Rate of Severe COPD Exacerbations Over the 52-week Treatment Period
A severe COPD exacerbation was defined as new or increased COPD symptoms that lead to hospitalization (duration \> 24 hours) or death. The unadjusted AER was estimated as the total number of exacerbations observed over the treatment period divided by the total participant-years at risk (participant-years = date of first study drug administration to completion or discontinuation during the double-blind treatment period divided by 365.25 days). The adjusted AER was estimated using negative binomial regression. Adjusted rate values have been reported. A method of dispersion was not specified in the SAP.
Time frame: Up to 52 weeks
Number of Participants With Treatment-emergent Adverse Events (TEAEs), Including Serious Adverse Events (SAEs), and Adverse Events of Special Interest (AESIs)
An AE was defined as any untoward medical occurrence in a clinical study participant temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study intervention. An SAE was defined as any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent disability or incapacity; is a congenital anomaly or birth defect; is medically significant. An AESI was defined as any of the following: cases of potential drug-induced liver injury; suspected transmission of an infectious agent by a study treatment; major adverse cardiovascular events (MACE); anaphylaxis, anaphylactoid, and hypersensitivity reactions.
Time frame: Up to a maximum of 62 weeks
Number of Participants Who Died or Discontinued Study Due to TEAEs
An AE was defined as any untoward medical occurrence in a clinical study participant temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study intervention. Participants who died or discontinued the study due to TEAEs will be reported here.
Time frame: Up to a maximum of 62 weeks
Serum Concentration of Astegolimab
Time frame: Up to a maximum of 62 weeks
Number of Participants With Anti-drug Antibodies (ADAs) to Astegolimab
Participants were considered to be ADA positive if they were ADA negative at baseline but developed an ADA response following astegolimab administration (treatment-induced ADA response), or if they were ADA positive at baseline and the titer of one or more post-baseline samples was greater than the titer of the baseline sample by a scientifically reasonable margin such as at least 0.60 titer unit (t.u.) greater than the baseline titer result (treatment-enhanced ADA response).
Time frame: Up to a maximum of 62 weeks
A total of 1382 participants with chronic obstructive pulmonary disease (COPD) who were former or current smokers and had a history of frequent exacerbations took part in the study at 319 investigative sites across 35 countries. The study is still ongoing; data for an additional Japan extension cohort that was not part of the primary analysis will be submitted upon final study completion.
| Milestone | Astegolimab Q2W | Astegolimab Q4W | Placebo |
|---|---|---|---|
| Started | 460 | 461 | 459 |
| Safety-evaluable (se) population | 464 | 462 | 449 |
| Completed | 404 | 411 | 404 |
| Not completed | 56 | 50 | 55 |
| Withdrew: Adverse event | 8 | 3 | 5 |
| Withdrew: Death | 11 | 18 | 14 |
| Withdrew: Lost to follow-up | 2 | 3 | 6 |
| Withdrew: Reason not specified | 0 | 2 | 2 |
| Withdrew: Physician decision | 3 | 2 | 3 |
| Withdrew: Protocol violation | 2 | 0 | 3 |
| Withdrew: Withdrawal by subject | 30 | 22 | 22 |
A moderate COPD exacerbation was defined as new or increased COPD symptoms (e.g., dyspnea, sputum volume, and sputum purulence) that lead to treatment (duration ≥ 3 days) with systemic corticosteroids (oral, intravenous \[IV\], or intramuscular \[IM\]) at a dose of \> 10 milligrams per day (mg/day) prednisolone equivalent and/or antibiotics. A severe COPD exacerbation was defined as new or increased COPD symptoms that lead to hospitalization (duration \> 24 hours) or death. The unadjusted AER was estimated as the total number of exacerbations observed over the treatment period divided by the total participant-years at risk (participant-years = date of first study drug administration to completion or discontinuation during the double-blind treatment period divided by 365.25 days). The adjusted AER was estimated using negative binomial regression. Adjusted rate values have been reported. A method of dispersion was not specified in the SAP.
| Exacerbation per participant year | Astegolimab Q2W | Astegolimab Q4W | Placebo |
|---|---|---|---|
| Annualized Rate of Moderate and Severe COPD Exacerbations Over the 52-week Treatment Period | 1.000 (0.722 to 1.011) | 0.963 (0.695 to 0.975) | 1.171 |
A moderate COPD exacerbation was defined as new or increased COPD symptoms (e.g., dyspnea, sputum volume, and sputum purulence) that lead to treatment (duration ≥ 3 days) with systemic corticosteroids (oral, intravenous \[IV\], or intramuscular \[IM\]) at a dose of \> 10 milligrams per day (mg/day) prednisolone equivalent and/or antibiotics. A severe COPD exacerbation was defined as new or increased COPD symptoms that lead to hospitalization (duration \> 24 hours) or death. The unadjusted AER was estimated as the total number of exacerbations observed over the treatment period divided by the total participant-years at risk (participant-years = date of first study drug administration to completion or discontinuation during the double-blind treatment period divided by 365.25 days). The adjusted AER was estimated using negative binomial regression. Adjusted rate values have been reported A method of dispersion was not specified in the SAP.
| Exacerbation per participant-year | Astegolimab Q2W | Astegolimab Q4W | Placebo |
|---|---|---|---|
| Annualized Rate of Moderate and Severe COPD Exacerbations Over the 52-week Treatment Period in Participants With Low Baseline Blood Eosinophil Level (<300 Cells Per Microliter [Cells/µL]) | 0.989 (0.730 to 1.042) | 0.969 (0.715 to 1.022) | 1.134 |
Time to first moderate or severe COPD exacerbation was defined as the time from the first administration of study drug to the first incidence of moderate or severe COPD exacerbation event during the 52-week treatment period. A moderate COPD exacerbation was defined as new or increased COPD symptoms (e.g., dyspnea, sputum volume, and sputum purulence) that lead to treatment (duration ≥3 days) with systemic corticosteroids (oral, IV, or IM) at a dose of \>10 mg/day prednisolone equivalent and/or antibiotics. A severe COPD exacerbation was defined as new or increased COPD symptoms that lead to hospitalization (duration \> 24 hours) or death. Kaplan-Meier (K-M) method was used to estimate the median time.
| weeks | Astegolimab Q2W | Astegolimab Q4W | Placebo |
|---|---|---|---|
| Time to First Moderate or Severe COPD Exacerbation During the 52-week Treatment Period | 47.1 (39.6 to NA) | 45.6 (39.3 to NA) | 38.7 (33.9 to 47.7) |
SGRQ-C is a disease-specific, self-administered instrument designed to assess the impact of COPD on participants' health status and well-being based on their perception of COPD-related experiences. The questionnaire consists of 40 items across three sub-domains: symptoms (respiratory symptoms and severity- 7 items), activity (activities causing or limited by breathlessness-13 items) and impacts (social functioning and psychological disturbances due to airway disease- 20 items). Each response is assigned a unique empirically derived weight. Total score is calculated by summing the weights to all the positive responses across each domain, with scores ranging from 0 (no impairment) to 100 (maximum impairment), with lower scores indicating better HRQoL. Adjusted mean of change from baseline (CFB) is reported here.
| score on a scale | Astegolimab Q2W | Astegolimab Q4W | Placebo |
|---|---|---|---|
| Absolute Change From Baseline in Health-related Quality-of-life (HRQoL) at Week 52, as Assessed Through the Saint George's Respiratory Questionnaire-COPD (SGRQ-C) Total Score | -7.374 ± 0.888 | -7.644 ± 0.875 | -6.601 ± 0.883 |
Post-bronchodilator FEV1 was defined as the FEV1 value measured with spirometry 20-30 minutes after bronchodilator use. Maximal bronchodilation was achieved via administration of either albuterol (90 micrograms \[µg\] metered dose) or salbutamol (100 µg metered dose), with or without a spacer device, up to a maximum of 4 inhalations. Adjusted mean of CFB is reported here.
| liters | Astegolimab Q2W | Astegolimab Q4W | Placebo |
|---|---|---|---|
| Absolute Change From Baseline in Post-bronchodilator Forced Expiratory Volume in 1 Second (FEV1) (Liters) at Week 52 | -0.008 ± 0.011 | -0.025 ± 0.011 | -0.022 ± 0.011 |
The EXAcerbations of Chronic Pulmonary Disease Tool (EXACT) is a 14-item participant-reported instrument used to assess the frequency, severity, and duration of COPD exacerbations using a daily electronic diary (eDiary). It includes four domains: breathlessness (5 items), cough and sputum (3 items), chest symptoms (3 items), and additional attributes (tired or weak, sleep disturbance, and scared or worried; 3 items). The E-RS:COPD is an 11-item subset of the EXACT designed to assess the severity of cardinal respiratory symptoms of COPD, including breathlessness, cough, sputum, chest congestion, and chest tightness. It consists of three subscales: RS-Breathlessness, RS-Cough \& Sputum, and RS-Chest Symptoms. Items are scored on 5- or 6-point Likert scales, and the total score is calculated by summing the item scores, ranging from 0 (no impact) to 40 (high impact), with higher scores indicating greater symptom severity. Adjusted mean of CFB is reported here.
| score on a scale | Astegolimab Q2W | Astegolimab Q4W | Placebo |
|---|---|---|---|
| Absolute Change From Baseline in Evaluating Respiratory Symptoms in COPD (E-RS: COPD) Total Score at Week 52 | -2.281 ± 0.283 | -1.880 ± 0.277 | -2.230 ± 0.280 |
Percentage of participants with SGRQ-C improvement was defined as the percentage of participants with an absolute decrease from baseline of ≥4 points in SGRQ-C total score. SGRQ-C is a disease-specific, self-administered instrument designed to assess the impact of COPD on participants' health status and well-being based on their perception of COPD-related experiences. The questionnaire consists of 40 items across three sub-domains: symptoms (respiratory symptoms and severity- 7 items), activity (activities causing or limited by breathlessness-13 items) and impacts (social functioning and psychological disturbances due to airway disease- 20 items). Each response is assigned a unique empirically derived weight. Total score is calculated by summing the weights to all the positive responses across each domain, with scores ranging from 0 (no impairment) to 100 (maximum impairment), with lower scores indicating better HRQoL.
| percentage of participants | Astegolimab Q2W | Astegolimab Q4W | Placebo |
|---|---|---|---|
| Percentage of Participants With Improvement in HRQoL at Week 52, as Assessed by SGRQ-C | 58.5 | 53.7 | 48.5 |
A severe COPD exacerbation was defined as new or increased COPD symptoms that lead to hospitalization (duration \> 24 hours) or death. The unadjusted AER was estimated as the total number of exacerbations observed over the treatment period divided by the total participant-years at risk (participant-years = date of first study drug administration to completion or discontinuation during the double-blind treatment period divided by 365.25 days). The adjusted AER was estimated using negative binomial regression. Adjusted rate values have been reported. A method of dispersion was not specified in the SAP.
| Exacerbation per participant-year | Astegolimab Q2W | Astegolimab Q4W | Placebo |
|---|---|---|---|
| Annualized Rate of Severe COPD Exacerbations Over the 52-week Treatment Period | 0.136 (0.472 to 0.948) | 0.168 (0.588 to 1.160) | 0.204 |
An AE was defined as any untoward medical occurrence in a clinical study participant temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study intervention. An SAE was defined as any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent disability or incapacity; is a congenital anomaly or birth defect; is medically significant. An AESI was defined as any of the following: cases of potential drug-induced liver injury; suspected transmission of an infectious agent by a study treatment; major adverse cardiovascular events (MACE); anaphylaxis, anaphylactoid, and hypersensitivity reactions.
Results for this outcome have not been posted.
An AE was defined as any untoward medical occurrence in a clinical study participant temporally associated with the use of a study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study intervention. Participants who died or discontinued the study due to TEAEs will be reported here.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Participants were considered to be ADA positive if they were ADA negative at baseline but developed an ADA response following astegolimab administration (treatment-induced ADA response), or if they were ADA positive at baseline and the titer of one or more post-baseline samples was greater than the titer of the baseline sample by a scientifically reasonable margin such as at least 0.60 titer unit (t.u.) greater than the baseline titer result (treatment-enhanced ADA response).
Results for this outcome have not been posted.
Collected over Up to 62 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Astegolimab Q2W | 11/464 (2.4%) | 113/464 (24.4%) | 243/464 (52.4%) |
| Astegolimab Q4W | 18/462 (3.9%) | 124/462 (26.8%) | 275/462 (59.5%) |
| Placebo | 15/449 (3.3%) | 107/449 (23.8%) | 267/449 (59.5%) |
| Event | Astegolimab Q2W | Astegolimab Q4W | Placebo |
|---|---|---|---|
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 62/464 | 68/462 | 67/449 |
| PneumoniaInfections and infestations | 17/464 | 14/462 | 18/449 |
| COVID-19Infections and infestations | 3/464 | 1/462 | 6/449 |
| Infective exacerbation of chronic obstructive airways diseaseInfections and infestations | 3/464 | 1/462 | 5/449 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 2/464 | 3/462 | 5/449 |
| Lower respiratory tract infectionInfections and infestations | 2/464 | 4/462 | 4/449 |
| Cerebral infarctionNervous system disorders | 0/464 | 4/462 | 0/449 |
| Cardiac failureCardiac disorders | 0/464 | 0/462 | 3/449 |
| DeathGeneral disorders and administration site conditions | 2/464 | 3/462 | 3/449 |
| InfluenzaInfections and infestations | 2/464 | 2/462 | 3/449 |
| Event | Astegolimab Q2W | Astegolimab Q4W | Placebo |
|---|---|---|---|
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 178/464 | 208/462 | 198/449 |
| Upper respiratory tract infectionInfections and infestations | 51/464 | 50/462 | 45/449 |
| NasopharyngitisInfections and infestations | 33/464 | 43/462 | 29/449 |
| DiarrhoeaGastrointestinal disorders | 18/464 | 12/462 | 28/449 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 18/464 | 19/462 | 24/449 |
| HeadacheNervous system disorders | 12/464 | 18/462 | 23/449 |
Intent-to-treat (ITT) population included all randomized participants, whether or not the participant received the assigned treatment, with participants grouped according to the treatment assigned at randomization.
| Age, Continuous(years) | Astegolimab Q2W | Astegolimab Q4W | Placebo | Total |
|---|---|---|---|---|
| Mean | 66.8 ± 7.5 | 66.6 ± 7.4 | 66.8 ± 6.9 | 66.7 ± 7.3 |
| Sex: Female, Male(Participants) | Astegolimab Q2W | Astegolimab Q4W | Placebo | Total |
|---|---|---|---|---|
| Female | 172 | 164 | 156 | 492 |
| Male | 288 | 297 | 303 | 888 |
| Ethnicity (NIH/OMB)(Participants) | Astegolimab Q2W | Astegolimab Q4W | Placebo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 66 | 67 | 71 | 204 |
| Not Hispanic or Latino | 384 | 378 | 371 | 1133 |
| Unknown or Not Reported | 10 | 16 | 17 | 43 |
| Race (NIH/OMB)(Participants) | Astegolimab Q2W | Astegolimab Q4W | Placebo | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 4 | 4 | 3 | 11 |
| Asian | 106 | 101 | 115 | 322 |
| Native Hawaiian or Other Pacific Islander | 4 | 0 | 1 | 5 |
| Black or African American | 20 | 35 | 21 | 76 |
| White | 320 | 310 | 311 | 941 |
| More than one race | 1 | 0 | 2 | 3 |
| Unknown or Not Reported | 5 | 11 | 6 | 22 |
Showing the first 100 of 348 sites across 36 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
Ran from Dec 2022 to primary completion in Jun 2025, 29 months.
Results were first posted in Oct 2026, 1 year 4 months after primary completion.
Of 108 industry-sponsored phase 3 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 36. This study's 29 months is above that.
Counting every sponsor, half of 141 studies reached it within 23 months; a quarter within 14 and three quarters within 44.
Completion moved once since we started tracking on Sep 25, 2026: Sep 2027 → Aug 2026, on Oct 28, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Astegolimab
Pulmonary Disease, Chronic Obstructive →